<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850432</url>
  </required_header>
  <id_info>
    <org_study_id>CMRPG3F1311</org_study_id>
    <nct_id>NCT02850432</nct_id>
  </id_info>
  <brief_title>Clinical and MRI Cardiac Biomarkers on Peripheral Arterial Disease in Patients With Long Term DM</brief_title>
  <acronym>CMRPADDM</acronym>
  <official_title>The Evolution and Impact of Clinical and MRI Cardiac Biomarkers on Peripheral Arterial Disease in Patients With Long Term DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to establish a clinically feasible simultaneous evaluation of heart&#xD;
      and lower limb using MRI and to assess the combined benefit of clinical and cardiac MRI&#xD;
      imaging markers in the evaluation of PAD and prediction of treatment outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We expect to enroll about 60 long-term DM patients (&gt;10 years) from main study. Patient will&#xD;
      receive evaluation of the perfusion in the lower limb by using blood oxygenation-level&#xD;
      dependent (BOLD) sequence with measurement of the extracellular volume fraction (ECV) as an&#xD;
      indicator of fibrosis severity in calf muscles. All patients will receive cardiac MRI&#xD;
      (cardiac function, ischemia and fibrosis) and MR angiography (severity of PAD). The baseline&#xD;
      studies will be completed within 2 years and 3 additional follow-up studies will be performed&#xD;
      by the end of 4th year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 1, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-treatment improvement of peripheral artery disease</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the combined benefit of clinical and MRI imaging parameters (cardiac and lower extremities) in treatment response monitoring and treatment outcome prediction.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Invasive treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rehabilitation with medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Invasive treatment</intervention_name>
    <description>Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol</description>
    <arm_group_label>Invasive treatment</arm_group_label>
    <other_name>Surgery or endovascular treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conservative treatment</intervention_name>
    <description>rehabilitation with medical therapy</description>
    <arm_group_label>Conservative treatment</arm_group_label>
    <other_name>rehabilitation with medical therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The inclusion criteria include:&#xD;
&#xD;
          1. Able to understand and provide signed informed consent&#xD;
&#xD;
          2. DM history of 10 years and above&#xD;
&#xD;
          3. Willing to receive 3 MRI follow-up and serum hematocrit examinations within 2 years,&#xD;
             if applicable&#xD;
&#xD;
          4. Willing to receive standard therapy such as surgery or medication&#xD;
&#xD;
          5. Age between 18-80 years old&#xD;
&#xD;
        The exclusion criteria include:&#xD;
&#xD;
          1. Pregnant or breast-feeding women&#xD;
&#xD;
          2. Allergic MRI contrast medium&#xD;
&#xD;
          3. Absolute contraindications to contrast MRI (e.g., metallic hazards, hemodynamic&#xD;
             instability, pregnancy, known allergy to contrast medium).&#xD;
&#xD;
          4. Contraindicated to MRI study: cardiac pacemaker, cochlear implantation, metallic&#xD;
             object within eyeball&#xD;
&#xD;
          5. Patients that refuse to, or has poor ability of understanding and comply study&#xD;
             conditions, such as severe dementia or difficulty in mobility&#xD;
&#xD;
          6. Patients having dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Hsiang Juan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Hsiang Juan, MD</last_name>
    <phone>+886-9-753-66388</phone>
    <email>Jonat126@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Gueishan</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Hsiang Juan, MD</last_name>
      <phone>+886-9-75366388</phone>
      <email>Jonat126@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Yu-Hsiang Juan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Ching Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Chin Chang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen-Ming Sung</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiun-jie Wang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gigin Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun-Chung Cheung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shu-Hang Ng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koon-Kwan Ng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jim Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Chun Lin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Yu-Hsiang Juan</investigator_full_name>
    <investigator_title>Primary investigator</investigator_title>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Extracellular volume matrix fraction</keyword>
  <keyword>Peripheral artery disease</keyword>
  <keyword>Blood-oxygen level dependent</keyword>
  <keyword>Cardiac function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We have to see if this corresponds to the IRB regulation.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

